QR-Code

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Background: The synergistic effects of antiangiogenic inhibitor bevacizumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) therapy were encouraging in patients with EGFR-mutant advanced NSCLC, though some controversy remains. The specific subgroup of patients who might be...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, Shiyun He, Hongying Liao
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2024-01-01
Schriftenreihe:Frontiers in Pharmacology
Schlagworte:
EGFR
NSCLC
bevacizumab
EGFR-TKI
combination therapy
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fphar.2023.1238579/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge